2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
In our exclusive interview, Dr. Aggarwal and Dr. Gandara discuss the evolution of liquid biopsy in lung cancer, explain the clinical implications of recent liquid biopsy approvals, and forecast the future of liquid biopsy in the field.
Welcome to OncLive On Air™! I’m your host today, Jessica Hergert.
OncLive On Air™ is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
Today, we had the pleasure of speaking with Charu Aggarwal, MD, MPH, a medical oncologist at Abramson Cancer Center and the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania’s Perelman School of Medicine, and David R. Gandara, MD, director of the Thoracic Oncology Program, professor, and senior advisor to the director of the University of California Davis Comprehensive Cancer Center, as well as a 2017 Giant of Cancer Care® in Lung Cancer, to discuss the role of liquid biopsy in lung cancer.
In our exclusive interview, Aggarwal and Gandara discussed the evolution of liquid biopsy in lung cancer, explained the clinical implications of recent liquid biopsy approvals, and forecasted the future of liquid biopsy in the field.